CMBA
PLX icon

C.M. Bidwell & Associates’s Protalix BioTherapeutics PLX Stock Holding History

C.M. Bidwell & Associates’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$512 Buy
+236
New +$586 ﹤0.01% 466

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

C.M. Bidwell & Associates's PLX Position: Q1 2026 in Review

C.M. Bidwell & Associates opened a new position in Protalix BioTherapeutics (PLX) in Q1 2026: 236 shares worth $512. The stake represents ﹤0.01% of the portfolio and ranks #466 among its holdings.

99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • C.M. Bidwell & Associates held 236 shares of Protalix BioTherapeutics worth $512 as of Q1 2026.
  • Protalix BioTherapeutics was a new C.M. Bidwell & Associates position in Q1 2026.
  • Protalix BioTherapeutics made up ﹤0.01% of C.M. Bidwell & Associates's portfolio in Q1 2026, its #466 holding.
  • 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2026, filed 15 May 2026.